Analysis of efficacy of the SGLT2 inhibitor alone or in combination with the DPP-4 inhibitor on urinary and plasma DPP-4 activities in obese patients with type 2 diabetes.
- Conditions
- Type 2 diabetes mellitus
- Registration Number
- JPRN-UMIN000019098
- Lead Sponsor
- Graduate School of Medicine, University of the Ryukyus
- Brief Summary
Canagliflozin(Cana) 12-week administration improved HbA1c, plasma DPP4 activity, BW, BMI, VFM, abdominal circumference, fasting serum glucose, fasting serum insulin, serum C-peptide, and ALT. Among the 12 cases, HbA1c, AST, and ALT were decreased and heart rate was increased in the group (12W vs.24W) that was combined with Teneligliptin(Tene) in 9 cases.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 12
Not provided
1) Under treatment with SGLT2 inhibitor,DPP-4 inhibitor, insulin, or GLP-1 analog 2) Severe ketosis, diabetic coma, or diabetic precoma within the past six months 3) Type 1 diabetes 4) Pituitary gland dysfunction, adrenal gland dysfunction 5) Severe infectious diseases, pre or post surgery, and serious trauma 6) Pregnant women, women suspected of being pregnant, or lactating women 7) Severe renal function disorder (eGFR < 45) 8) Severe liver function disorder 9) History of malignant tumor 10) Cardiac arrest (class of IV in NYHA) 11) Self-contained device such as pacemakers 12) Wearable devices such as Holter electrocardiographs 13) Implantable metallic medical devices
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method